Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CTLT Stock Forecast 2025-2026
$0.00
Current Price
$0
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CTLT Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
CTLT Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
0.0%
1 Year Change
0.0%
Year-to-Date Change
nan%
From 52W High of $0.00
nan%
From 52W Low of $0.00
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Catalent (CTLT) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CTLT and similar high-potential opportunities.
Latest CTLT Stock Price Targets & Analyst Predictions
Comprehensive analyst forecasts are currently unavailable for CTLT. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CTLT Analyst Ratings
0
Buy
0
Hold
0
Sell
CTLT Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.00
Latest CTLT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CTLT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
(CTLT) Competitors
The following stocks are similar to Catalent based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
(CTLT) Financial Data
has a market capitalization of $0 with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of N/A and return on equity of N/A.
Valuation Metrics
Market Cap
$0
Enterprise Value
$0
P/E Ratio
0.0x
PEG Ratio
0.0x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
EPS Growth
N/A
Financial Health
Cash/Price Ratio
nan%
Current Ratio
0.0x
Debt/Equity
0.0x
ROE
N/A
ROA
N/A
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
(CTLT) Business Model
(CTLT) Latest News & Analysis
Latest News
Quick Summary
Lisata Therapeutics has partnered with Catalent to explore the use of certepetide in antibody-drug conjugate applications, entering a research license agreement for SMARTag dual-payload ADCs.
Why It Matters
Lisata Therapeutics' collaboration with Catalent on certepetide enhances its ADC pipeline, potentially driving innovation and value, which could positively impact stock performance.
Source: Proactive Investors
Market Sentiment:
Positive
Quick Summary
Lisata Therapeutics (NASDAQ:LSTA) has signed a research license with Catalent to evaluate its peptide candidate, certepetide, using Catalent's ADC platform for preclinical testing on advanced solid tumors.
Why It Matters
Lisata's partnership with Catalent enhances its drug development capabilities, potentially accelerating the path to market for certepetide, which could drive future revenue and stock value.
Source: Proactive Investors
Market Sentiment:
Positive
Catalent Announces New Board Appointments
2 months ago
Quick Summary
Catalent, Inc. has appointed Susan Mahony, Marie-France Tschudin, and Tim Walbert to its Board of Directors, aiming for continued growth under Novo Holdings' ownership.
Why It Matters
The appointment of experienced board members signals strategic growth and stability for Catalent, potentially enhancing investor confidence and future performance under Novo Holdings.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Novo Holdings plans to double the size of Catalent, its recently acquired contract drugmaker, over five years, anticipating a focus on U.S. manufacturing under President-elect Trump.
Why It Matters
Novo Holdings' plan to expand Catalent signals potential growth in the contract drug manufacturing sector, influencing investor confidence in biotech and pharma stocks amid U.S. manufacturing trends.
Source: Reuters
Market Sentiment:
Positive
Quick Summary
Novo Holdings has finalized its $16.5 billion acquisition of Catalent, following the fulfillment of all regulatory closing conditions.
Why It Matters
Novo Holdings' acquisition of Catalent for $16.5 billion signals confidence in the contract drug manufacturing sector, potentially influencing stock valuations and market dynamics in pharmaceuticals.
Source: Reuters
Market Sentiment:
Neutral
Novo Holdings Completes Acquisition of Catalent
4 months ago
Quick Summary
Novo Holdings has acquired Catalent, Inc. for approximately $16.5 billion in an all-cash transaction. Alessandro Maselli will continue as President and Chief Executive Officer.
Why It Matters
Catalent's acquisition by Novo Holdings for $16.5 billion signals significant consolidation in the life sciences sector, potentially impacting market competition and stock valuations.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About CTLT Stock
What is 's (CTLT) stock forecast for 2025?
Analyst forecasts for (CTLT) are not currently available. The stock is trading at $0.00.
Is CTLT stock a good investment in 2025?
Analyst ratings for CTLT are not currently available. The stock is currently trading at $0.00. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CTLT stock?
Price predictions from Wall Street analysts for CTLT are not currently available. The stock is trading at $0.00.
What is 's business model?
N/A
What is the highest forecasted price for CTLT ?
Price targets from Wall Street analysts for CTLT are not currently available. The stock is trading at $0.00.
What is the lowest forecasted price for CTLT ?
Price targets from Wall Street analysts for CTLT are not currently available. The stock is trading at $0.00.
What is the overall CTLT consensus from analysts for ?
Analyst ratings for CTLT are not currently available. The stock is trading at $0.00.
How accurate are CTLT stock price projections?
Stock price projections, including those for , are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 13, 2025 8:44 AM UTC